ACTC Advanced Cell Technology, Inc., a biotechnology

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2013 at 7:50 PM

ACTC Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic, induced Pluripotency (iPS), and adult stem cell technology in the field of regenerative medicine Operations The company’s business is focused on both the development and commercialization of adult stem cell therapies and therapies based on cells derived from embryonic stem (ES) cells or other potentially totipotent stem cell technologies. The company’s adult stem cell-based products are specifically targeted at therapies for heart and other cardiovascular disease and are at a more advanced stage of development than its human ES cell based technologies. Its first human ES cell-based product, retinal pigmented epithelial cells, have entered Phase I clinical trials and various patients have already been treated. The company’s intellectual property includes patent rights and applications for specific applications of stem cell technology in producing retinal pigment epithelium (RPE) cells, hemangioblasts, myoblast stem cells, and various methods and compositions for the use of these technologies and derived cells in treating retinal and other eye disease, inflammatory and autoimmune diseases, and heart disease, as well as to provide agents for wound healing and replacement of blood components. Human ES Cell Programs The company’s research and technologies are focused on solving this obstacle by creating stem cell therapeutics with compatible tissues or which can be used in immunopriveleged or immunosuppressed sites of transplantation in patients. Compatible tissues are referred to as being histocompatible. The company has developed an alternative to inner cell mass (ICM)-derivation of human embryonic cell (hESC) - a method which utilizes single cell biopsy to remove a single blastomere from a 4-8 cell preembryo in a manner which does not result in the destruction of the preembryo. The company’s human ES cell technologies comprise cellular reprogramming and pluripotent stem cell technologies to produce cells that have the proliferative capacity of ES cells with therapeutic application and compatible with the patient. Cell Therapy Research Programs The company’s research in this area includes projects focusing on developing different cell types that may be used in the future to treat a range of diseases. Its researchers have generated stable RPE cell lines for use in its clinical retinal program and are working on projects to generate stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. Its cell therapy research programs include RPE and hemangioblast programs. The hemangioblast program is in preclinical development. Adult Stem Cell Program The company’s adult stem cell-based program is developing an autologous myoblast transplantation therapy delivered using a minimally invasive catheter injection system to restore cardiac function in patients with advanced heart disease. The key target for the therapy would be heart failure patients with New York Heart Association (NYHA) scores Class II to IV. The company's therapy could also benefit patients supported on ventricular assistance devices and potential additional indications, such as acute myocardial infarction, peripheral artery disease, and non-cardiac tissue repair. Intellectual Property The company’s research and development is supported by an intellectual property portfolio. It owns or has licenses to approximately 35 patents and has approximately 170 patent applications pending worldwide in the field of regenerative medicine and stem cell therapy. The company also has non-exclusive rights to a portfolio of patents and patent applications that support its core intellectual property. Collaborative Agreements In 2011, the company entered into a definitive collaborative agreement with Roslin Cells LTD (Roslin Cells) of Scotland. The company would work together to establish a bank of Good Manufacturing Practice (GMP)-grade human ES cell (hESC) lines using its patented, proprietary ‘single-cell blastomere’ technique for deriving hESC lines without destroying embryos. Regulations The company, in addition to safety regulations enforced by the US Food and Drug Administration (FDA), is also subject to regulations under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, and other present and potential future and federal, state, local, and foreign regulations.

Ocata Therapeutics Inc. (OCAT) Stock Research Links

OCAT Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovative Breaker Bar Reinvents Torque Application

A Fresh Take for Do-It-Yourselfers Ever tried to budge a stubborn bolt and felt like you were arm wrestling a gorilla? This is why a Winter Garden, Florida inventor has stepped up to the plate with the "BREAK IT," an adjustable breaker bar that promises to make this grimy task much smoother. Forget the days of waving around a cumbersome cheater bar. With this gadget,...

Bimbo Bakeries Teamsters Gear Up for Strike in NJ

A Brewing Storm at Bimbo Bakeries The morning air in East Brunswick fills with more than just the scent of fresh bread; there’s a tension you can slice through with a butter knife. Unwavering and fired-up, over 90 workers at Bimbo Bakeries have thrown their hats into the ring, ready to strike to protect something as sacred as the dough they churn—Teamsters' health...

Expedera Teams Up with Cadence for Edge AI Supercharge

A New Power Couple in AI Expedera and Cadence have decided to stir up the edge AI waters with their latest collaboration. By linking Expedera's Origin™ Evolution NPU with Cadence's Tensilica NeuroEdge 130 AI Co-Processor, we're looking at a partnership that's hell-bent on redefining efficiency and performance in edge AI systems. Breaking Down the Collaboration This...

Reindeer Expands With Google Cloud Marketplace Launch

Reindeer Rides Google Cloud's Tailwinds Alright, folks, here's a new twist in the world of enterprise AI that's got my eyeballs popped. Reindeer, that plucky outfit from New York and Tel Aviv, has cozied up with Google Cloud in a move that's set to turn heads in the sector. Now, you might hear "agentic AI" and think it's just some fancy jargon, but this is where it gets...

WSIB Slashes Registration Time with Guidewire Boost

Quick Fix: Streamlining Ontario's Employer Registration Alright, let's cut through the formalities and tell it like it is: Ontario's Workplace Safety and Insurance Board (WSIB) isn't messing around anymore. They've yanked their antiquated paper-laden process into the digital age, slicing the employer registration wait down from an agonizing eight to ten-day ordeal to a...

Coframe Nets $35M for AI-Driven 'Living Internet'

Transforming Digital Experiences with AI If you're tired of seeing the same dull homepage every time you visit a website, Coframe's got news for you. This startup scored a hefty $35 million to fund its vision—a 'Living Internet' that learns and adapts to each visitor. Khosla Ventures and Hanabi Capital are banking on this runaway train—that's commitment to tech...

Unquiet Nights' New Tune Echoes Rome's Eternal Lingering

Irish Rockers Unquiet Nights Celebrate a Poignant Release Ever heard of a band that takes its darn sweet time? Well, Unquiet Nights just dropped a single after sitting on it for a solid 15 years. 'Last Days of Rome' isn’t just a new tune; it’s a love letter to both music and the eternal echoes of Rome’s history. These Belfast rockers have been crafting this piece...

Honeywell Faces Investor Scrutiny: Class Action Deadline Looms

Clouds Gather Over Honeywell Aerospace Sometimes the storm clouds are about as subtle as an elephant in your garden. And that's precisely what's brewing over at Honeywell Aerospace, Inc. (NASDAQ: HONA) these days. November 23, 2026, looms large as the deadline for investors to jump on board with a class action tied to alleged missteps that caught everyone off guard. The...

Stocks Jump Ahead of Critical Inflation Reports

Stocks Lift as Wall Street Awaits Inflation Data Every trader's favorite game—speculation—returns as major U.S. stock benchmarks kick off Monday with some gusto. The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all saw gains in the early morning session, signaling positive vibes across the board. Numbers don't lie, folks: The S&P climbed...

Ridero Innovates with $2.7M to Tackle Auto Finance Woes

Ridero Gets Serious About Fixing Auto Financing When you've got startups like Ridero stepping up with a $2.7 million cash infusion, you can't help but sit up and listen. These folks are charging head-on into the automotive financing jumble, and they're bringing some high-tech toys to the party. With RiverPark Ventures and a slew of other big-name backers, Ridero's dialing...